2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2491

Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
Abstract Number: 2981

Prognostic Value of the Complex P2X7 Receptor-Inflammasome in Patients with Primary Sjögren’s Syndrome at Lymphoma Risk
Abstract Number: 3017

Program Evaluation of ‘the Joint Clinic’: An Innovative Clinical Service for Patients with Hip or Knee Osteoarthritis
Abstract Number: 2723

Programmed Death 1 Inhibits T-Cell Adhesion By Regulating Rap1
Abstract Number: 749

Progranulin Overproduction Due to Fli1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor a in Systemic Sclerosis
Abstract Number: 2830

Progression to and Type of Orthopaedic Surgery in Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Abstract Number: 1693

Progressive Disease in Systemic Sclerosis after One Year of Follow-up; Results of a Standardized Multidisciplinary Health Care Program
Abstract Number: 837

Progressive Multifocal Leukoencephalopathy Associated with Biologic Therapy in Rheumatic Diseases: Strengthening Association with Rituximab
Abstract Number: 1198

Prolactin Is Locally Produced in the Synovium of Patients with Inflammatory Arthritic Diseases and Promotes Macrophage Activation
Abstract Number: 1947

Prolactin Promotes Survival of Immature B Cells from MRL/Lpr Mice
Abstract Number: 330

Prolactin Reduces Bone Erosion in Adjuvant-Induced Arthritis
Abstract Number: 1738

Prominent Role of CCR6+ T Helper Cells in the Pathogenesis of ACPA+ Patients with Early RA
Abstract Number: 1238

Proportion of Peripheral Plasmacytoid Dendritic Cells and Plasmablasts Reflects Disease Activity in IgG4-related Disease
Abstract Number: 85

Protective Association of HLA-DRB1*13:02 Against MPO-ANCA Positive ANCA-Associated Vasculitis in a Japanese Population
Abstract Number: 2452

Protective Effect of the IL33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].